Skip to main content
Premium Trial:

Request an Annual Quote

Signal Genetics Regains Compliance With Nasdaq Listing Requirement

NEW YORK (GenomeWeb) – Signal Genetics said today that it has received a letter from Nasdaq notifying the company that it has regained compliance with the Nasdaq Capital Market's minimum bid price requirement for continued listing.

The letter noted that as of Nov. 21 the company evidenced a closing bid price of its common stock in excess of the $1 minimum requirement for at least 10 consecutive trading days.

Earlier this month Signal and Miragen Therapeutics announced their plans to merge, to divest Signal's molecular diagnostic assets, and to form a company fully focused on Miragen's microRNA therapeutics programs.

As part of the deal, which is expected to close in the first quarter of 2017, privately held Miragen will pick up Signal's Nasdaq listing.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.